OpenAI has acquired Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the company announced Tuesday. The financial terms were not disclosed.
Orchestra’s team and platform will be folded into Rosalind, OpenAI’s family of AI models and tools for biologists and chemists. The acquisition follows OpenAI’s launch of GPT-Rosalind, a model built specifically for biology and drug discovery, and a companion product called Rosalind Workbench that connects the model to scientific tools and data.
What Orchestra’s agents do
Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—map how setbacks such as a failed manufacturing batch ripple through a drug program. They identify which activities and deadlines are affected, gather relevant information, and compare possible responses, while scientists and program leaders make the final decision.
OpenAI said the combined team will build agents that connect scientific findings with the decisions and follow-up studies needed to turn a promising result into an actual medicine. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement.
The costly, lengthy path to market
Getting a new medicine from first idea to U.S. approval can take up to 15 years, according to OpenAI. Bringing one approved drug to market can cost more than $2.6 billion, and fewer than 10% of candidates that enter human testing ever make it to pharmacy shelves.
Beyond the science itself, OpenAI says drug teams must coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug.
Competitive context
The deal follows Anthropic’s roughly $400 million purchase of AI biotech startup Coefficient Bio in April, as rival AI labs race to own the workflow behind new medicines. Anthropic also launched a research platform called Claude Science in June.
Founded in the fall of 2022, Orchestra raised its seed round from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to Caplight data. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO.
OpenAI did not say what it paid for Orchestra or when its agents will show up inside Rosalind. Its previous Rosalind announcement came just five days earlier, when it offered eligible U.S. university labs up to 30 free seats for as long as 12 months through a new Rosalind Academic Plan.
